Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.
Looking for a particular Ambrx employee's phone or email?
Ambrx Questions
The Ambrx annual revenue was $5.2 million in 2026.
Shawn Zhang is the Chief Scientific Officer and GM China of Ambrx.
64 people are employed at Ambrx.
Ambrx is based in San Diego, California.
The NAICS codes for Ambrx are [32, 325414, 32541, 325, 54, 541, 3254].
The SIC codes for Ambrx are [873, 283, 87, 28].
Top Ambrx Employees
-
Shawn Zhang
Chief Scientific Officer and GM China at Ambrx
San Diego, CA, US25 -
Lawson MacArtney
President and Chief Executive Officer at Ambrx
Spring City, PA, US25+ -
Lawson MacArtney
President and CEO at Ambrx
Spring City, PA, US22 -
Douglas Greene
Vice President, Clinical Pharmacology at Ambrx
San Clemente, CA, US45+ -
Ricardo Burgos
Senior Director Quality at Ambrx
San Diego, CA, US22
Related Companies
